New developments in the treatment and prevention of vascular disease-part 1

Current Pharmaceutical Design

Volumn 16, Issue 34, 2010, Pages 3767-3768

  Katsiki, N ^a   Athyros, V G ^a   Mikhailidis, D P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMFEBUTAMONE; ANACETRAPIB; ANTIANDROGEN; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; CLOPIDOGREL; COLESEVELAM; DIPYRIDAMOLE; ESTROGEN; EZETIMIBE; FIBRINOGEN; GLUCOSE; HEPATITIS C VACCINE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MIPOMERSEN; NALTREXONE; NUTRACEUTICAL; PRASUGREL; PROTEIN INHIBITOR; RIMONABANT; SIBUTRAMINE; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; TETRAHYDROLIPSTATIN; TICAGRELOR; TORCETRAPIB; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL DIFFERENTIATION; COMBINATION CHEMOTHERAPY; CONVALESCENCE; DIABETES MELLITUS; DIABETIC ANGIOPATHY; DIET; DIETARY INTAKE; EDITORIAL; ENDOTHELIUM CELL; ESTROGEN THERAPY; FAMILIAL HYPERCHOLESTEROLEMIA; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOSTASIS; HEPATITIS C; HERBAL MEDICINE; HIGH RISK PATIENT; HUMAN; INSULIN RESISTANCE; KIDNEY DISEASE; LIFESTYLE MODIFICATION; MECHANOTRANSDUCTION; METABOLIC SYNDROME X; MONOTHERAPY; NUTRITIONAL ASSESSMENT; OBESITY; PLEIOTROPY; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SEX DIFFERENCE; SHEAR STRESS; SIGNAL TRANSDUCTION; STEM CELL; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE; VIRAL CLEARANCE;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; MALE;

EID: 79551635897     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161210794455094     Document Type: Editorial

References (45)

1. Bountziouka V, Panagiotakos DB. Statistical methods used for the evaluation of reliability and validity of nutrition assessment tools used in medical research. Curr Pharmaceutical Design 2010; 16(34): 3770-75.
2. Omar EA, Kama A, Alqahtania A, et al. Herbal medicines and nutraceuticals for diabetic vascular complications: mechanisms of action and bioactive phytochemicals. Curr Pharm Des 2010; 16(34): 3776-807.
3. Mitsios JV, Papathanasiou AI, Goudevenos JA, Tselepis AD. The antiplatelet and antithrombotic actions of statins. Curr Pharm Des 2010; 16(34): 3808-14.
4. Lioudaki E, Ganotakis ES, Mikhailidis DP, Nair DR. The estrogenic burden on vascular risk in male-to-female transsexuals. Curr Pharm Des 2010; 16(34): 3815-22.
5. Trpkovic A, Stokic E, Radak D, et al. Chronic hepatitis C, insulin resistance and vascular disease. Curr Pharm Des 2010; 16(34): 3823-29.
6. Hardman TC, Rutherford P, Dubrey SW, Wierzbicki AS. Sodium-glucose co-transporter 2 inhibitors: from apple tree to 'sweet pee'. Curr Pharm Des 2010; 16(34): 3830-38.
7. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Preventing type 2 diabetes mellitus: Room for residual risk reduction after lifestyle changes? Curr Pharm Des 2010; 16(34): 3839-47.
8. Tan A, Sumpio BE, Lee S, Helms JA, Seifalian AM. The implications of human stem cell differentiation to endothelial cell via fluid shear stress in cardiovascular regenerative medicine: A review. Curr Pharm Des 2010; 16(34): 3848-61.
9. Mikhailidis DP, Sibbring GC, Ballantyne CM, Davies GM, Catapano AL. Meta-analysis of the cholesterol-lowering effect of ezetimibe added to ongoing statin therapy. Curr Med Res Opin 2007; 23: 2009-26.
10. Florentin M, Liberopoulos EN, Mikhailidis DP, Elisaf MS. Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia. Curr Med Res Opin 2008; 24: 995-1009.
11. Tziomalos K, Athyros VG, Mikhailidis DP. Colesevelam improves glycemic control and lipid management in inadequately controlled type 2 diabetes mellitus. Nat Clin Pract Endocrinol Metab 2009; 5: 16-7.
12. Huijgen R, Abbink EJ, Bruckert E, et al. Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther 2010; 32: 615-25.
13. Olsson AG. Laropiprant plus niacin for dyslipidemia and prevention of cardiovascular disease. Expert Opin Pharmacother 2010; 11: 1715-26.
14. Athyros VG, Tziomalos K, Karagiannis A, Mikhailidis DP. Statin-fibrate combination for mixed dyslipidaemia: a limited option? Curr Med Res Opin 2010; 26: 2137-40.
15. ACCORD Study Group, Ginsberg HN, Elam MB, Lovato LC, et al. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 2010; 362:1563-74.
16. Sharma M, Ansari MT, Abou-Setta AM, et al. Systematic review: comparative effectiveness and harms of combination therapy and monotherapy for dyslipidemia. Ann Intern Med 2009; 151: 622-30.
17. Ansquer JC, Foucher C, Aubonnet P, Le Malicot K. Fibrates and microvascular complications in diabetes--insight from the FIELD study. Curr Pharm Des 2009; 15: 537-52.
18. Ray KK, Seshasai SRK, Erqou S, et al. Statins and all-cause mortality in high-risk primary prevention: a meta-analysis of 11 randomized controlled trials involving 65 229 participants. Arch Intern Med 2010; 170: 1024-31.
19. Thavendiranathan P, Bagai A, Brookhart MA, Choudhry NK. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Arch Intern Med 2006; 166: 2307-13.
20. Brugts JJ, Yetgin T, Hoeks SE, et al. The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338: b2376.
21. Patel N, Hegele RA. Mipomersen as a potential adjunctive therapy for hypercholesterolemia. Expert Opin Pharmacother 2010; 11: 2569-72.
22. Athyros VG, Kakafika A, Tziomalos K, Karagiannis A, Mikhailidis DP. Cholesteryl ester transfer protein inhibition and HDL increase: has the dream ended? Expert Opin Investig Drugs 2008; 17: 445-9.
23. Dogan S, Duivenvoorden R, Grobbee DE, et al. Ultrasound protocols to measure carotid intima-media thickness in trials; comparison of reproducibility, rate of progression, and effect of intervention in subjects with familial hypercholesterolemia and subjects with mixed dyslipidemia. Ann Med 2010; 42: 447-64.
24. Vergeer M, Bots ML, van Leuven SI, et al. Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation 2008; 118: 2515-22.
25. Nissen SE, Tardif JC, Nicholls SJ, et al. Effect of torcetrapib on the progression of coronary atherosclerosis. N Engl J Med 2007; 356: 1304-16.
26. Barter PJ, Caulfield M, Eriksson M, et al. Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med 2007; 357: 2109-22.
27. Coccheri S. Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors. Drugs 2010; 70: 887-908.
28. Marczewski MM, Postula M, Kosior D. Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor. Vasc Health Risk Manag 2010; 6: 419-29.
29. Bonaca M, Giugliano RP. Antithrombotics in acute coronary syndromes: updates from the past year. Curr Treat Options Cardiovasc Med 2010; 12: 84-99.
30. Cheng AY, Leiter LA. Glucose lowering and cardiovascular disease: what do we know and what should we do? Eur J Cardiovasc Prev Rehabil 2010; 17 Suppl 1: S25-31.
31. Drab SR. Incretin-based therapies for type 2 diabetes mellitus: current status and future prospects. Pharmacotherapy 2010; 30: 609-24.
32. Alberti KG, Eckel RH, Grundy SM, et al. International diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; international association for the study of obesity. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; american heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation 2009; 120: 1640-5.
33. Le Foll B, Gorelick DA, Goldberg SR. The future of endocannabinoid-oriented clinical research after CB1 antagonists. Psychopharmacology (Berl) 2009; 205: 171-4.
34. Czernichow S, Batty D. Withdrawal of sibutramine for weight loss: where does this leave clinicians? Obes Facts 2010; 3: 155-6.
35. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf 2008; 31: 53-65.
36. Plodkowski RA, Nguyen Q, Sundaram U, Nguyen L, Chau DL, Jeor SS. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity. Expert Opin Pharmacother 2009; 10: 1069-81.
37. Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2010; 376: 595-605.
38. Gasparyan AY, Stavropoulos-Kalinoglou A, Mikhailidis DP, Toms TE, Douglas KM, Kitas GD. The rationale for comparative studies of accelerated atherosclerosis in rheumatic diseases. Curr Vasc Pharmacol 2010; 8: 437-49.
39. McCullough PA, Verrill TA. Cardiorenal interaction: appropriate treatment of cardiovascular risk factors to improve outcomes in chronic kidney disease. Postgrad Med 2010; 122: 25-34.
40. Tziomalos K, Weerasinghe CN, Mikhailidis DP, Seifalian AM. Vascular risk factors in South Asians. Int J Cardiol 2008; 128: 5-16.
41. Emerging Risk Factors Collaboration, Erqou S, Kaptoge S, Perry PL, et al. Lipoprotein (a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. JAMA 2009; 302: 412-23.
42. He LP, Tang XY, Ling WH, Chen WQ, Chen YM. Early C-reactive protein in the prediction of long-term outcomes after acute coronary syndromes: a meta-analysis of longitudinal studies. Heart 2010; 96: 339-46.
43. Buckley DI, Fu R, Freeman M, Rogers K, Helfand M. C-reactive protein as a risk factor for coronary heart disease: a systematic review and metaanalyses for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 483-95.
44. Athyros VG, Kakafika AI, Karagiannis A, Mikhailidis DP. Do we need to consider inflammatory markers when we treat atherosclerotic disease? Atherosclerosis 2008; 200: 1-12.
45. Helfand M, Buckley DI, Freeman M, et al. Emerging risk factors for coronary heart disease: a summary of systematic reviews conducted for the U.S. Preventive Services Task Force. Ann Intern Med 2009; 151: 496-507.